Workshop  ||| S:0 E:9 ||| JJ
report ||| S:9 E:15 ||| NN
:  ||| S:15 E:17 ||| :
Crystal  ||| S:17 E:25 ||| NNP
City  ||| S:25 E:30 ||| NNP
V--quantitative  ||| S:30 E:46 ||| JJ
bioanalytical  ||| S:46 E:60 ||| JJ
method  ||| S:60 E:67 ||| NN
validation  ||| S:67 E:78 ||| NNS
and  ||| S:78 E:82 ||| CC
implementation ||| S:82 E:96 ||| NN
:  ||| S:96 E:98 ||| :
the  ||| S:98 E:102 ||| DT
2013  ||| S:102 E:107 ||| CD
revised  ||| S:107 E:115 ||| JJ
FDA  ||| S:115 E:119 ||| NNP
guidance  ||| S:119 E:128 ||| NN
In  ||| S:128 E:131 ||| IN
September  ||| S:131 E:141 ||| NNP
2013 ||| S:141 E:145 ||| CD
,  ||| S:145 E:147 ||| ,
the  ||| S:147 E:151 ||| DT
FDA  ||| S:151 E:155 ||| NNP
released  ||| S:155 E:164 ||| VBD
a  ||| S:164 E:166 ||| DT
draft  ||| S:166 E:172 ||| NN
revision  ||| S:172 E:181 ||| NN
of  ||| S:181 E:184 ||| IN
the  ||| S:184 E:188 ||| DT
Bioanalytical  ||| S:188 E:202 ||| NNP
Method  ||| S:202 E:209 ||| NNP
Validation  ||| S:209 E:220 ||| NNP
( ||| S:220 E:221 ||| -LRB-
BMV ||| S:221 E:224 ||| NNP
)  ||| S:224 E:226 ||| -RRB-
Guidance ||| S:226 E:234 ||| NNP
,  ||| S:234 E:236 ||| ,
which  ||| S:236 E:242 ||| WDT
included  ||| S:242 E:251 ||| VBD
a  ||| S:251 E:253 ||| DT
number  ||| S:253 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
changes  ||| S:263 E:271 ||| NNS
to  ||| S:271 E:274 ||| TO
the  ||| S:274 E:278 ||| DT
expectations  ||| S:278 E:291 ||| NNS
for  ||| S:291 E:295 ||| IN
bioanalysis ||| S:295 E:306 ||| NN
,  ||| S:306 E:308 ||| ,
most  ||| S:308 E:313 ||| RBS
notably  ||| S:313 E:321 ||| RB
the  ||| S:321 E:325 ||| DT
inclusion  ||| S:325 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
biomarker  ||| S:338 E:348 ||| JJ
assays  ||| S:348 E:355 ||| NN
and  ||| S:355 E:359 ||| CC
data ||| S:359 E:363 ||| NNS
.  ||| S:363 E:365 ||| .
To  ||| S:365 E:368 ||| TO
provide  ||| S:368 E:376 ||| VB
a  ||| S:376 E:378 ||| DT
forum  ||| S:378 E:384 ||| NN
for  ||| S:384 E:388 ||| IN
an  ||| S:388 E:391 ||| DT
open ||| S:391 E:395 ||| JJ
,  ||| S:395 E:397 ||| ,
inclusive  ||| S:397 E:407 ||| JJ
discussion  ||| S:407 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
the  ||| S:421 E:425 ||| DT
revised  ||| S:425 E:433 ||| JJ
draft  ||| S:433 E:439 ||| NN
BMV  ||| S:439 E:443 ||| NNP
Guidance ||| S:443 E:451 ||| NNP
,  ||| S:451 E:453 ||| ,
the  ||| S:453 E:457 ||| DT
AAPS  ||| S:457 E:462 ||| NNP
and  ||| S:462 E:466 ||| CC
FDA  ||| S:466 E:470 ||| NNP
once  ||| S:470 E:475 ||| RB
again  ||| S:475 E:481 ||| RB
collaborated  ||| S:481 E:494 ||| VBD
to  ||| S:494 E:497 ||| TO
convene  ||| S:497 E:505 ||| VB
a  ||| S:505 E:507 ||| DT
two-and-a-half  ||| S:507 E:522 ||| JJ
day  ||| S:522 E:526 ||| NN
workshop  ||| S:526 E:535 ||| NN
during  ||| S:535 E:542 ||| IN
early  ||| S:542 E:548 ||| JJ
December  ||| S:548 E:557 ||| NNP
2013  ||| S:557 E:562 ||| CD
in  ||| S:562 E:565 ||| IN
Baltimore ||| S:565 E:574 ||| NNP
,  ||| S:574 E:576 ||| ,
MD ||| S:576 E:578 ||| NNP
,  ||| S:578 E:580 ||| ,
USA ||| S:580 E:583 ||| NNP
.  ||| S:583 E:585 ||| .
The  ||| S:585 E:589 ||| DT
resulting  ||| S:589 E:599 ||| JJ
format  ||| S:599 E:606 ||| NN
embodied  ||| S:606 E:615 ||| VBN
extensive  ||| S:615 E:625 ||| JJ
open  ||| S:625 E:630 ||| JJ
discussion  ||| S:630 E:641 ||| NN
and  ||| S:641 E:645 ||| CC
each  ||| S:645 E:650 ||| DT
thematic  ||| S:650 E:659 ||| JJ
session  ||| S:659 E:667 ||| NN
included  ||| S:667 E:676 ||| VBD
only  ||| S:676 E:681 ||| RB
brief ||| S:681 E:686 ||| JJ
,  ||| S:686 E:688 ||| ,
concise  ||| S:688 E:696 ||| JJ
descriptions  ||| S:696 E:709 ||| NNS
by  ||| S:709 E:712 ||| IN
Agency  ||| S:712 E:719 ||| NNP
and  ||| S:719 E:723 ||| CC
industry  ||| S:723 E:732 ||| NN
representatives  ||| S:732 E:748 ||| NNS
prior  ||| S:748 E:754 ||| RB
to  ||| S:754 E:757 ||| TO
opening  ||| S:757 E:765 ||| VBG
the  ||| S:765 E:769 ||| DT
floor  ||| S:769 E:775 ||| NN
discussion ||| S:775 E:785 ||| NN
.  ||| S:785 E:787 ||| .
The  ||| S:787 E:791 ||| DT
Workshop  ||| S:791 E:800 ||| NNP
was  ||| S:800 E:804 ||| VBD
built  ||| S:804 E:810 ||| VBN
around  ||| S:810 E:817 ||| IN
four  ||| S:817 E:822 ||| CD
thematic  ||| S:822 E:831 ||| CD
sessions  ||| S:831 E:840 ||| NNS
( ||| S:840 E:841 ||| -LRB-
Common  ||| S:841 E:848 ||| NNP
Topics ||| S:848 E:854 ||| NNP
,  ||| S:854 E:856 ||| ,
Chromatographic ||| S:856 E:871 ||| NNP
,  ||| S:871 E:873 ||| ,
Ligand-Binding  ||| S:873 E:888 ||| NNP
Assays ||| S:888 E:894 ||| NNP
,  ||| S:894 E:896 ||| ,
and  ||| S:896 E:900 ||| CC
Biomarkers ||| S:900 E:910 ||| NNP
)  ||| S:910 E:912 ||| -RRB-
and  ||| S:912 E:916 ||| CC
a  ||| S:916 E:918 ||| DT
final  ||| S:918 E:924 ||| JJ
session  ||| S:924 E:932 ||| NN
with  ||| S:932 E:937 ||| IN
international  ||| S:937 E:951 ||| JJ
regulators ||| S:951 E:961 ||| NNS
,  ||| S:961 E:963 ||| ,
concluding  ||| S:963 E:974 ||| VBG
with  ||| S:974 E:979 ||| IN
a  ||| S:979 E:981 ||| DT
review  ||| S:981 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
the  ||| S:991 E:995 ||| DT
outcomes  ||| S:995 E:1004 ||| NN
and  ||| S:1004 E:1008 ||| CC
recommendations  ||| S:1008 E:1024 ||| NNS
from  ||| S:1024 E:1029 ||| IN
the  ||| S:1029 E:1033 ||| DT
thematic  ||| S:1033 E:1042 ||| JJ
sessions ||| S:1042 E:1050 ||| NNS
.  ||| S:1050 E:1052 ||| .
This  ||| S:1052 E:1057 ||| DT
Workshop  ||| S:1057 E:1066 ||| JJ
report  ||| S:1066 E:1073 ||| NN
summarizes  ||| S:1073 E:1084 ||| VBD
the  ||| S:1084 E:1088 ||| DT
outcomes  ||| S:1088 E:1097 ||| NN
and  ||| S:1097 E:1101 ||| CC
includes  ||| S:1101 E:1110 ||| VBZ
topics  ||| S:1110 E:1117 ||| NNS
of  ||| S:1117 E:1120 ||| IN
agreement ||| S:1120 E:1129 ||| NN
,  ||| S:1129 E:1131 ||| ,
those  ||| S:1131 E:1137 ||| DT
where  ||| S:1137 E:1143 ||| WRB
the  ||| S:1143 E:1147 ||| DT
FDA  ||| S:1147 E:1151 ||| NNP
will  ||| S:1151 E:1156 ||| MD
consider  ||| S:1156 E:1165 ||| VB
the  ||| S:1165 E:1169 ||| DT
Industry ||| S:1169 E:1177 ||| NNP
's  ||| S:1177 E:1180 ||| POS
perspective ||| S:1180 E:1191 ||| NN
,  ||| S:1191 E:1193 ||| ,
and  ||| S:1193 E:1197 ||| CC
those  ||| S:1197 E:1203 ||| DT
where  ||| S:1203 E:1209 ||| WRB
the  ||| S:1209 E:1213 ||| DT
workshop  ||| S:1213 E:1222 ||| NN
provided  ||| S:1222 E:1231 ||| VBD
a  ||| S:1231 E:1233 ||| DT
first  ||| S:1233 E:1239 ||| JJ
open  ||| S:1239 E:1244 ||| JJ
dialogue ||| S:1244 E:1252 ||| NN
.  ||| S:1252 E:1254 ||| .
This  ||| S:1254 E:1259 ||| DT
article  ||| S:1259 E:1267 ||| NN
will  ||| S:1267 E:1272 ||| MD
be  ||| S:1272 E:1275 ||| VB
available  ||| S:1275 E:1285 ||| JJ
to  ||| S:1285 E:1288 ||| TO
the  ||| S:1288 E:1292 ||| DT
bioanalytical  ||| S:1292 E:1306 ||| JJ
community  ||| S:1306 E:1316 ||| NN
at  ||| S:1316 E:1319 ||| IN
http ||| S:1319 E:1323 ||| NNS
: ||| S:1323 E:1324 ||| :
-www.aaps.org ||| S:1324 E:1337 ||| CD
/ ||| S:1337 E:1338 ||| CD
BMV13  ||| S:1338 E:1344 ||| CD
.  ||| S:1344 E:1346 ||| .
